Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?

Key Takeaways Bristol Myers Squibb will continue the phase III ADEPT-2 study on Cobenfy in Alzheimer's psychosis.The study's readout shifts to next year following data review and a committee recommendation.Cobenfy's early schizophrenia sales hit $105M as it targets broader indications across Alzheimer's programs.Bristol Myers Squibb (BMY) recently announced that it will continue the phase III ADEPT-2 study on Cobenfy in psychosis associated with Alzheimer's disease.The decision to continue the study follows ...